Trevi Therapeutics, Inc. (TRVI)
After hours:
| Previous close | 2.6800 |
| Open | 2.7000 |
| Bid | 2.6400 x 300 |
| Ask | 2.7000 x 300 |
| Day's range | 2.5700 - 2.7000 |
| 52-week range | 0.9700 - 4.0000 |
| Volume | |
| Avg. volume | 221,143 |
| Market cap | 188.062M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending investor and medical conferences in July and August. In addition, Trevi is pleased to announce that abstracts on the ongoing Phase 2b CORAL and Phase 2a RIVER trials were accepted
- PR Newswire
Trevi Therapeutics to Participate in Upcoming Conferences
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending investor, business development and medical conferences in May and June.
- PR Newswire
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced financial results for the quarter ended March 31, 2024, as well as provided business updates.
